Ianalumab is a fully human monoclonal antibody designed to deplete B cells via antibody-dependent cellular toxicity and inhibit BAFF-R-mediated signals of B cell function and survival.

Martin Sjögren will join the Chicago Stars in January as their new coach. Anders Jacobson, Sjögren’s first assistant, will ...

Phase 3 results position telitacicept as potential best-in-disease profile in primary Sjögren's disease Telitacicept ...

What to expect from the Chicago Stars following the Martin Sjögren hire - Attacking Third ...

The Chicago Stars have named former Norway women’s national team coach Martin Sjögren as the National Women’s Soccer League ...

The questionable resume, and relaxed timeline of Sjögren's hiring leave more questions than answers around Stars' future ...

Sjögren, who currently is head coach of Hammarby in the Swedish Damallsvenskan league, will join the Stars for the start of ...

"Novartis’ mAb could become first Sjögren’s disease drug after Phase III success" was originally created and published by ...

Sjögren, who is currently head coach of Hammarby in Sweden’s top women’s flight, will join the club in January.

Novartis may have abandoned one Sjögren's syndrome asset this year, but it looks like the drugmaker has a winner on its hands ...

The China-based phase 3 trial of telitacicept in primary Sjögren's syndrome (pSS) met its primary endpoint, which focused on ...

Primary Sjögren’s syndrome is a common systemic autoimmune disease, with a female-to-male predominance of 9:1 and peak incidence at approximately 50 years of age. 1 The hallmark of the disease ...